Plant-based pipeline Leverage Jaguar Health’s focus on plant-based, non-opioid prescription medicines and their collaborations (Napo Pharmaceuticals, Magdalena Biosciences) to position strategic partnerships or co-development opportunities around GI distress, CNS, and mental health indications with a sustainability angle.

Animal health expansion Target veterinary channels with Neonorm Dog and other Jaguar Animal Health assets for distribution partnerships, veterinary clinics, and pet-focused pharma retailers seeking natural, non-opioid GI and CID-related therapies for companion animals.

European access Capitalize on Jaguar’s minority/majority stakes and presence in Europe via Napo Therapeutics to explore licensing, market access, and distribution deals for crofelemer-derived products across EU markets, especially where plant-based therapies are gaining regulatory traction.

Clinical and investor buzz Engage investors and pharma partners by aligning with ongoing trial readouts and abstracts in pediatric GI, MVID, SBS, and CID indications, offering collaboration on clinical programs, pharma-grade manufacturing, or co-promotion in aligned markets.

Digital and compliance edge Utilize Jaguar’s technology stack and digital engagement capabilities (Cloudflare, MySQL, PHP, HTTP/3) to support CRM, data-driven partnership scouting, and compliant digital outreach to healthcare professionals and veterinary networks, accelerating partner discovery and due diligence.